PlainPatent
USPTO 2015–2025 USPTO PatentsView US Corporation

La Jolla Pharmaceuticals Company

USPTO PatentsView assignee record - 5 granted patents across 9 technology areas, recorded in grant years 2015–2020. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

RSS updates for this company
Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, La ranks #48,267 of 49,997 tracked US assignees by granted-patent volume, with 5 patents across 9 technology areas.

#48,267
of 49,997 US assignees by volume
19th percentile
by Innovation Score (26.0/100)
15.4
avg claims per patent
-33%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R48267 · US Corporation #48,267 · 5 grants

GRANTS-MICRO · BOTTOM-DECILE · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DOWN · BOOK-FULL

  • GRANTS-MICRO 5 grants
  • BOTTOM-DECILE #48,267/49,997
  • PHOTO-FINISH La Montagne Verte
  • CPC-NARROW A61P · 9 areas
  • INNOV-THIN 26.0/100
  • CLAIMS-RICH 15.4 claims/avg
  • TYPE-USCORP US Corporation
  • VEL-DOWN -33% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: La Montagne Verte (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Innovation-score neighbourhood around La

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows La's Innovation Score is 26.0/100 (19th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Where La's grants concentrate

La Jolla Pharmaceuticals Company is a focused PatentsView assignee: 9 CPC subclasses with 80% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2020 (2 grants) versus a trough of 1 in 2015. By volume, La sits between Luxvisions Innovation Limited and Labyrinth Holdings, LLC.

Who files at La's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows La holds 5 patents at rank #48,391, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near La

By rank, the assignees closest to #48,391 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in La's primary technology class.

La's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

26 19th percentile higher than 19% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

0.511.522.5 2015201620192020 2
USPTO utility patent grants by year · 2015–2020

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
La Jolla Pharmaceuticals Company patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 1 20.0%
2016 1 20.0%
2019 1 20.0%
2020 2 40.0%

Which technologies does La Jolla Pharmaceuticals Company patent most?

Top 9 of 9 technology areas

Where it ranks

Overall rank by patents

#48,267

of 49,997 tracked assignees

Innovation Score

26.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

La Jolla Pharmaceuticals Company's patent record in context - here's where to go next.

  • La Jolla Pharmaceuticals Company's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 80% of its portfolio - see every assignee active in that class. Explore A61P
  • Ranked #48,267 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare La Jolla Pharmaceuticals Company against Luxvisions Innovation Limited, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 26.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page
  • USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.